Independent Risk Factors for Hepatocellular Carcinoma Recurrence after Direct-Acting Antiviral Therapy in Patients with Chronic Hepatitis C

Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. Methods: A total of 100 patients with HCV-r...

Full description

Saved in:
Bibliographic Details
Published in:Gut and liver 2021-05, Vol.15 (3), p.410
Main Authors: Young-hwan Ahn, Heirim Lee, Do Young Kim, Hye Won Lee, Su Jong Yu, Young Youn Cho, Jeong Won Jang, Byoung Kuk Jang, Chang Wook Kim, Hee Yeon Kim, Hana Park, Hyo Jung Cho, Bumhee Park, Soon Sun Kim, Jae Youn Cheong
Format: Article
Language:Korean
Subjects:
Antiviral agents
Carcinoma
chronic
Hepatitis C
hepatocellular
Re-currence
Risk factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background/Aims: This study was performed to evaluate the efficacy of direct-acting antivirals (DAAs) in Korean patients with hepatitis C virus (HCV)-related hepatocellular carcinoma (HCC) and to investigate the risk factors associated with HCC recurrence. Methods: A total of 100 patients with HCV-related HCC, who were treated with DAAs between May 2015 and December 2016, were recruited from seven university hospitals in Korea. Claim data of 526 patients with HCC obtained from the Health Insurance Review and Assessment Service in South Korea were used for external validation of the results. Results: Among the 100 patients, 88% achieved a sustained virological response (SVR) 12 weeks after the end of DAA therapy (SVR12), and 37% experienced HCC recurrence after DAA therapy. Short last HCC treatment durability (
ISSN:1976-2283